Research programme: antibody radionucleotide conjugates - Orano Med/Nordic Nanovector

Drug Profile

Research programme: antibody radionucleotide conjugates - Orano Med/Nordic Nanovector

Alternative Names: Anti-CD37 212Pb-ARC - Orano Med/Nordic Nanovector; Lead-212 conjugated anti-CD37 antibody - Orano Med/Nordic Nanovector

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AREVA Med; Nordic Nanovector
  • Developer Orano Med
  • Class Antibodies; Antineoplastics; Immunoconjugates; Radiopharmaceuticals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Leukaemia

Most Recent Events

  • 28 Jun 2016 Nordic Nanovector and AREVA Med enter into a research collaboration to develop lead-212 conjugated anti-CD37 antibody for Leukaemia
  • 28 Jun 2016 Preclinical trials in Leukaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top